Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of Serum Cholesterol and Statin Use in the Risk of Prostate Cancer Detection and Tumor Aggressiveness

  • Morote Robles, Juan|||0000-0002-2168-323X
  • Celma, Ana|||0000-0002-3128-3811
  • Planas Morin, Jacques|||0000-0002-0222-584X
  • Placer, José
  • de Torres, Inés|||0000-0002-5495-9140
  • Olivan, Mireia|||0000-0002-8464-0827
  • Carles, Joan|||0000-0002-9983-5934
  • Reventós, Jaume
  • Doll, Andreas|||0000-0001-8965-8682
The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC:.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of prostate tumor overexpressed 1 in cancer progression

  • Cánovas, Verónica|||0000-0002-1994-5763
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Paciucci, Rosanna|||0000-0001-5651-5933
Prostate-Tumor-Overexpressed-1 (PTOV1) is a conserved adaptor protein discovered as overexpressed in prostate cancer. Since its discovery, the number of binding partners and associated cellular functions has increased and helped to identify PTOV1 as regulator of gene expression at transcription and translation levels. Its overexpression is associated with increased tumor grade and proliferation in prostate cancer and other neoplasms, including breast, ovarian, nasopharyngeal, squamous laryngeal, hepatocellular and urothelial carcinomas. An important contribution to higher levels of PTOV1 in prostate tumors is given by the frequent rate of gene amplifications, also found in other tumor types. The recent resolution of the structure by NMR of the PTOV domain in PTOV2, also identified as Arc92/ACID1/MED25, has helped to shed light on the functions of PTOV1 as a transcription factor. In parallel, by studying its interaction with RACK1, we have discovered PTOV1 action in promoting mRNAs translation. Here, we will focus on the role of PTOV1 in cancer, re-examine its pro-oncogenic effects and re-evaluate the most relevant interactions and evidences of its cellular functions. The data are used to formulate a model for the mechanisms of action of PTOV1 in line with its recently described activities and cellular pathways modulated in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan, Mireia|||0000-0002-8464-0827
  • García, Marta
  • Suárez, Leticia|||0000-0002-3864-4616
  • Guiu, Marc|||0000-0002-7083-986X
  • Gros, Laura
  • Méndez Fernández, Olga
  • Rigau, Marina|||0000-0002-1691-454X
  • Reventós, Jaume
  • Segura, Miguel F.|||0000-0003-0916-3618
  • de Torres, Inés|||0000-0002-5495-9140
  • Planas, Jacques|||0000-0002-0222-584X
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Gomis, Roger R..|||0000-0001-6473-2858
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. Our main objective was to unveil novel molecules associated with choosing the bone as a metastatic niche. For this purpose, we generated and characterized a cell line with increased tropism to bone. Its molecular analysis has led us to identify factors with a potential role in bone metastasis that could also be used as biomarkers of disease progression. These data help us to understand the mechanisms that increase bone metastasis penetrance of PCa cells and could provide new therapeutic tools in the future for patients with worse prognoses. About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.